WHY IT MATTERS: Patients who have not found adequate relief from CBD or THC-based products may soon have access to better-studied CBG formulations targeting anxiety and cognitive symptoms, but those conversations with a clinician should happen before swapping or adding products. CLINICAL OVERVIEW: Cannabigerol (CBG) and its acidic precursor cannabigerolic acid (CBGA) are gaining serious scientific attention as researchers examine their potential roles in anxiety reduction, memory enhancement, and anti-cancer activity. CBGA is often called the “mother of cannabinoids” because it serves as the biosynthetic precursor from which THC, CBD, and CBC are all derived, making it a foundational compound in the cannabis plant’s chemistry.
First Human Clinical Trial: CBG Reduces Anxiety and Stress Without Intoxication
If Texas—one of America’s most conservative states and a major hemp producer—signals voter support for legalization, it could dramatically accelerate federal cannabis reform that affects your access to products. In one of the first double-blind, placebo-controlled clinical trials of isolated CBG in humans, a 20mg oral dose of hemp-derived cannabigerol produced statistically significant reductions in subjective anxiety and stress, along with improved verbal memory, without intoxication, cognitive slowing, or motor impairment. The study of 34 healthy adults suggests CBG may influence stress and anxiety pathways without producing typical ‘drug effects.’ Researchers emphasize preliminary nature and need for replication.